异氟烷吸入镇静用于急性低氧性呼吸衰竭机械通气成人:SAVE-ICU随机临床试验
SAVE-ICU是一项在加拿大14个ICU开展的实用性、实效性、开放标签、优效性随机临床试验,纳入786例因非COVID或COVID所致急性低氧性呼吸衰竭(PaO2:FIO2<300 mmHg)接受机械通气且镇静<72小时的成人。患者随机接受异氟烷吸入镇静策略(按需联用静脉辅助镇静)或常规静脉镇静策略,镇静目标由临床团队滴定至期望镇静评分。吸入组更多使用难治性低氧血症辅助治疗(63.9% vs 55.0%,组间差8.89%,95%CI 1.95%-15.83%),14天内谵妄和昏迷-free天数更少(组间差-0.95,95%CI -1.69至-0.22)。
要点
- 吸入组需联用静脉辅助镇静比例高:随机后前14天内任一日常规联用静脉镇静者为49.9%至55.4%。
- 吸入组难治性低氧血症辅助治疗使用更多:63.9% vs 55.0%,组间差8.89%(95%CI 1.95%-15.83%)。
- 吸入组14天内谵妄和昏迷-free天数更少:组间差-0.95(95%CI -1.69至-0.22)。
- ICU-free、 ventilator-free(30天)及hospital-free(60天)天数两组相似;3个月生活质量和残疾评分无差异。
适用人群与场景
- 加拿大14个ICU中≥18岁、因急性低氧性呼吸衰竭接受机械通气且镇静<72小时的成人;AHRF定义为PaO2:FIO2<300 mmHg,包括非COVID呼吸衰竭或COVID-19。
诊断标准与关键阈值
- AHRF诊断标准:PaO2与FIO2比值<300 mmHg。
- 镇静目标:由临床团队滴定至期望的镇静评分(原文未给出具体评分名称和界值)。
处置流程与药物剂量
- 第一步:筛选符合AHRF(PaO2:FIO2<300 mmHg)且机械通气、镇静<72小时的成人。
- 第二步:随机分配至异氟烷吸入镇静策略(按临床需要联用静脉辅助镇静)或常规静脉镇静策略。
- 第三步:由临床团队滴定镇静剂以达到期望的镇静评分,持续至拔管或死亡。
- 原文未提及异氟烷的具体剂量、单位、给药途径细节、频次或疗程。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:实用性、实效性、开放标签、优效性随机临床试验;14个加拿大ICU;786例随机,780例纳入主要分析(平均年龄61.1岁,女性34.0%,非COVID AHRF 73.7%,平均PaO2:FIO2 152.6 mmHg)。
- 次要终点:ICU-free、ventilator-free(30天)、hospital-free(60天)天数两组相似;吸入组难治性低氧血症辅助治疗更多(63.9% vs 55.0%,组间差8.89%,95%CI 1.95%-15.83%);14天谵妄和昏迷-free天数更少(组间差-0.95,95%CI -1.69至-0.22);3个月生活质量和残疾评分无差异。
证据类型、等级与局限
- 证据类型:随机临床试验(RCT),开放标签、实用性设计。
- 局限:开放标签设计;吸入组约半数患者联用静脉辅助镇静,可能稀释纯吸入镇静效应;原文未提及盲法。
对床旁实践的改变
- 对于AHRF机械通气成人,异氟烷吸入镇静策略不应被视为降低住院死亡率的措施;选择该策略时需预期约半数患者仍需联用静脉辅助镇静。
- 使用异氟烷吸入镇静需注意难治性低氧血症辅助治疗使用可能增多,以及谵妄和昏迷-free天数可能减少。
指南或共识出处
- SAVE-ICU随机临床试验,ClinicalTrials.gov Identifier: NCT04415060;发表于JAMA。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Rigorous evidence for inhaled sedation using isoflurane in mechanically ventilated patients with acute hypoxemic respiratory failure (AHRF) is limited.
OBJECTIVE: To evaluate whether an inhaled sedation strategy lowers hospital mortality compared with usual care intravenous sedation strategy in mechanically ventilated adults with AHRF.
DESIGN, SETTING, AND PARTICIPANTS: Pragmatic, effectiveness, open-label, superiority, randomized clinical trial in 14 intensive care units (ICUs) in Canada. Adults (≥18 years) receiving sedation for less than 72 hours and receiving mechanical ventilation for AHRF from non-COVID respiratory failure (ratio of partial pressure of arterial oxygen [Pao2] to fraction of inspired oxygen [Fio2] <300 mm Hg) or COVID-19 were enrolled between September 2020 and March 2025 with follow-up through June 2025.
INTERVENTION: Patients were randomized to an inhaled sedation strategy using isoflurane with intravenous adjuncts as clinically needed or to a usual intravenous sedation care strategy. Sedatives were titrated to achieve the desired target sedation score guided by clinical teams and continued until extubation or death.
MAIN OUTCOMES AND MEASURES: Primary outcome was all-cause hospital mortality. Secondary outcomes included ICU- and ventilator-free days at day 30; hospital-free days at day 60; use of refractory hypoxemia adjunctive therapies; delirium- and coma-free days at day 14; and quality-of-life and disability scores at 3 months.
RESULTS: Of 786 patients randomized, 780 were included in the primary analysis (mean age, 61.1 years; 34.0% female; 73.7% non-COVID AHRF, mean Pao2:Fio2 ratio, 152.6 mm Hg); 385 in the inhaled sedation and 395 in the intravenous sedation groups. In the inhaled sedation group, 49.9% to 55.4% of patients received concomitant intravenous sedation on any day during the first 14 days after randomization. At hospital discharge, 161 of 379 patients (42.5%) in the inhaled sedation group had died, compared with 171 of 390 patients (43.8%) in the intravenous sedation group (risk ratio, 0.98 [95% CI, 0.84 to 1.14]; P = .85). There was no effect modification in prespecified subgroup analyses for age, sex, and COVID-19 status. ICU-, ventilator-, and hospital-free days were similar between groups. The inhaled sedation group received more adjunctive therapies for hypoxemia (239 [63.9%] vs 214 [55.0%]; between-group difference, 8.89% [95% CI, 1.95% to 15.83%]) and had fewer delirium- and coma-free days (between-group difference, -0.95 [95% CI, -1.69 to -0.22]). There was no difference in quality-of-life and disability scores between groups.
CONCLUSIONS AND RELEVANCE: In mechanically ventilated adults with AHRF, an inhaled sedation strategy using isoflurane with intravenous adjuncts as clinically needed did not reduce hospital mortality compared with an intravenous sedation strategy.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04415060.
参考来源
- Jerath A, Slessarev M, Martin C, et al. Isoflurane-Based Inhaled Sedation in Mechanically Ventilated Adults With Acute Hypoxemic Respiratory Failure: The SAVE-ICU Randomized Clinical Trial. JAMA. 2026. PMID: 42872958. doi:10.1001/jama.2026.18471
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。